Long-term health-related quality of life in head and neck cancer survivors: A large multinational study.
cross-sectional
head and neck cancer
quality of life
survivor
treatment
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
05 Feb 2024
05 Feb 2024
Historique:
revised:
11
12
2023
received:
16
06
2023
accepted:
13
12
2023
medline:
5
2
2024
pubmed:
5
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
Head and neck cancer (HNC) patients suffer from a range of health-related quality of life (HRQoL) issues, but little is known about their long-term HRQoL. This study explored associations between treatment group and HRQoL at least 5 years' post-diagnosis in HNC survivors. In an international cross-sectional study, HNC survivors completed the European Organization for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (EORTC-QLQ-C30) and its HNC module (EORTC-QLQ-H&N35). Meaningful HRQoL differences were examined between five treatment groups: (a) surgery, (b) radiotherapy, (c) chemo-radiotherapy, (d) radiotherapy ± chemotherapy and neck dissection and (e) any other surgery (meaning any tumour surgery that is not a neck dissection) and radiotherapy ± chemotherapy. Twenty-six sites in 11 countries enrolled 1105 survivors. They had a median time since diagnosis of 8 years, a mean age of 66 years and 71% were male. After adjusting for age, sex, tumour site and UICC stage, there was evidence for meaningful differences (10 points or more) in HRQoL between treatment groups in seven domains (Fatigue, Mouth Pain, Swallowing, Senses, Opening Mouth, Dry Mouth and Sticky Saliva). Survivors who had single-modality treatment had better or equal HRQoL in every domain compared to survivors with multimodal treatment, with the largest differences for Dry Mouth and Sticky Saliva. For Global Quality of Life, Physical and Social Functioning, Constipation, Dyspnoea and Financial Difficulties, at least some treatment groups had better outcomes compared to a general population. Our data suggest that multimodal treatment is associated with worse HRQoL in the long-term compared to single modality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Organisation for Research and Treatment of Cancer
ID : EORTC-1629
Informations de copyright
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer. 2000;36:1796-1807.
Al-Mamgani A, Mehilal R, van Rooij PH, Tans L, Sewnaik A, Levendag PC. Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (chemo)radiation: the impact of treatment modality and radiation technique. Laryngoscope. 2012;122:1789-1795.
Bossi P, Cossu Rocca M, Corvo R, et al. The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. Crit Rev Oncol Hematol. 2017;116:82-88.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778-789.
Dittberner A, Friedl B, Wittig A, et al. Gender disparities in epidemiology, treatment, and outcome for head and neck cancer in Germany: a population-based long-term analysis from 1996 to 2016 of the Thuringian Cancer Registry. Cancer. 2020:12.
Braakhuis BJM, Leemans CR, Visser O. Incidence and survival trends of head and neck squamous cell carcinoma in The Netherlands between 1989 and 2011. Oral Oncol. 2014;50:670-675.
Janz TA, Graboyes EM, Nguyen SA, et al. A comparison of the NCDB and SEER database for research involving head and neck cancer. Otolaryngol Head Neck Surg. 2019;160:284-294.
Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122:155-164.
Hashim D, Genden E, Posner M, Hashibe M, Boffetta P. Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. Ann Oncol. 2019;30:744-756.
Lewis A, Kang R, Levine A, Maghami E. The new face of head and neck cancer: the HPV epidemic. Oncology (Williston Park). 2015;29:616-626.
Machiels J-P, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1462-1475.
Clasen D, Keszte J, Dietz A, et al. Quality of life during the first year after partial laryngectomy: longitudinal study. Head Neck. 2018;40:1185-1195.
Loorents V, Rosell J, Salgado Willner H, Borjeson S. Health-related quality of life up to 1 year after radiotherapy in patients with head and neck cancer (HNC). Springerplus. 2016;5:669.
Roick J, Danker H, Dietz A, Papsdorf K, Singer S. Predictors of changes in quality of life in head and neck cancer patients: a prospective study over a 6-month period. Eur Arch Otorhinolaryngol. 2020;277:559-567.
Tribius S, Raguse M, Voigt C, et al. Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: results of a prospective study. Strahlenther Onkol. 2015;191:501-510.
Goyal N, Day A, Epstein J, et al. Head and neck cancer survivorship consensus statement from the American Head and Neck Society. Laryngoscope Investig Otolaryngol. 2022;7:70-92.
Tribius S, Haladyn S, Hanken H, et al. Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlenther Onkol. 2021;197:219-230.
Scott SI, Kathrine Ø Madsen A, Rubek N, et al. Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer. Cancer Med. 2021;10:483-495.
Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope. 2005;115:678-683.
Al-Mamgani A, van Rooij P, Verduijn GM, Meeuwis CA, Levendag PC. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys. 2012;84:189-195.
Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope. 2005;115:2183-2192.
Nordgren M, Jannert M, Boysen M, et al. Health-related quality of life in patients with pharyngeal carcinoma: a five-year follow-up. Head Neck. 2006;28:339-349.
Nordgren M, Abendstein H, Jannert M, et al. Health-related quality of life five years after diagnosis of laryngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1333-1343.
Nordgren M, Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Boysen M, Jannert M. Quality of life in oral carcinoma: a 5-year prospective study. Head Neck. 2008;30:461-470.
Kraaijenga SA, Oskam IM, van der Molen L, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW. Evaluation of long term (10-years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer. Oral Oncol. 2015;51:787-794.
Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28:847-856.
Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol. 2013;49:443-448.
Tsai WL, Huang TL, Liao KC, et al. Impact of late toxicities on quality of life for survivors of nasopharyngeal carcinoma. BMC Cancer. 2014;14:856.
Yan YB, Meng L, Liu ZQ, et al. Quality of life in long-term oral cancer survivors: an 8-year prospective study in China. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:67-75.
Development ES. CHES [Internet]. Assessed August 3, 2022. https://ches.pro/
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
Locati LD, Galbiati D, Calareso G, et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer. 2020;126:1888-1894.
Takahashi M, Hwang M, Misiukiewicz K, et al. Quality of life analysis of HPV-positive oropharyngeal cancer patients in a randomized trial of reduced-dose versus standard chemoradiotherapy: 5-year follow-up. Front Oncol. 2022;12:859992.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
Taylor K, Singer S. Langzeitlebensqualität bei Patienten mit Kopf-Hals-Tumoren. Onkologie. 2019;25:253-261.
Hammerlid E, Adnan A, Silander E. Population-based reference values for the European Organization for Research and Treatment of Cancer Head and Neck module. Head Neck. 2017;39:2036-2047.
Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States. Eur J Cancer. 2019;107:153-163.
van Leeuwen M, Kieffer JM, Young TE, et al. Phase III study of the European Organisation for Research and Treatment of Cancer quality of life cancer survivorship core questionnaire. J Cancer Surviv Res Pract. 2023;17:1111-1130.
Singer S, Hammerlid E, Tomaszewska IM, et al. Methodological approach for determining the minimal important difference and minimal important change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the swallowing scale. Qual Life Res. 2022;31:841-853.
Musoro JZ, Coens C, Singer S, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. Head Neck. 2020;42:3141-3152.
Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48:1713-1721.
Jansen F, Snyder CF, Leemans CR, Verdonck-de Leeuw IM. Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer-specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer. Head Neck. 2016;38(Suppl 1):E1493-E1500.